CLINICAL TRIALS
Effects of a novel immune modulation therapy in patients with advanced chronic heart failure
Results of a randomized, controlled, phase II trial
Guillermo Torre-Amione, MD, PhD, FACC*,*,
François Sestier, MD ,
Branislav Radovancevic, MD and
James Young, MD
* Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas, USA
Hotel-Dieu du CHUM, Montreal, Quebec, Canada
Texas Heart Institute, Houston, Texas, USA
The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Manuscript received January 15, 2004;
revised manuscript received June 3, 2004,
accepted June 14, 2004.
* Reprint requests and correspondence: Dr. Guillermo Torre-Amione, Methodist DeBakey Heart Center and Baylor College of Medicine, 6550 Fannin, Suite 1901, Houston, Texas 77030 (Email: gtorre{at}bcm.tmc.edu).
OBJECTIVE: We sought to determine whether a novel, non-pharmacological form of immune modulation therapy (IMT), shown experimentally to reduce inflammatory and increase anti-inflammatory cytokines, improved outcomes in patients with advanced heart failure (HF).
BACKGROUND: Immune activation contributes to the progression of HF, but treatments directed against inflammation have been largely unsuccessful.
METHODS: Seventy-five HF patients (New York Heart Association [NYHA] functional class III to IV) were randomized to receive either IMT (n = 38) or placebo (n = 37) in a double-blind trial for six months, with continuation of standard HF therapy. Patients were evaluated using the 6-min walk test, changes in NYHA functional class, cardiac function, and quality of life assessments, as well as occurrence of death and hospitalization.
RESULTS: There was no between-group difference in 6-min walk test, but 15 IMT patients (compared with 9 placebo) improved NYHA functional classification by at least one class (p = 0.140). The Kaplan-Meier survival analysis showed that IMT significantly reduced the risk of death (p = 0.022) and hospitalization (p = 0.008). Analysis of a clinical composite score demonstrated a significant between-group difference (p = 0.006). There was no difference in left ventricular ejection fraction, but there was a trend toward improved quality of life (p = 0.110).
CONCLUSIONS: These preliminary findings are consistent with the hypothesis that immune activation is important in the pathogenesis of HF and establish the basis for a phase III trial to define the benefit of IMT in chronic HF.
|
Abbreviations and Acronyms
| | HF = heart failure | | IMT = immune modulation therapy | | LVEF = left ventricular ejection fraction | | NYHA = New York Heart Association | | TNF = tumor necrosis factor |
|
This article has been cited by other articles:
|
|
|
|
 
J. G.F. Cleland, A. P. Coletta, and A. L. Clark
Clinical trials update from the joint European Society and World Congress of Cardiology meeting: PEP-CHF, ACCLAIM and the HHH study
Eur J Heart Fail,
October 1, 2006;
8(6):
658 - 661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Jankowska, P. Ponikowski, M. F. Piepoli, W. Banasiak, S. D. Anker, and P. A. Poole-Wilson
Autonomic imbalance and immune activation in chronic heart failure - Pathophysiological links
Cardiovasc Res,
June 1, 2006;
70(3):
434 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
December 6, 2005;
46(11):
2125 - 2133.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Thum, J. Bauersachs, P. A. Poole-Wilson, H.-D. Volk, and S. D. Anker
The Dying Stem Cell Hypothesis: Immune Modulation as a Novel Mechanism for Progenitor Cell Therapy in Cardiac Muscle
J. Am. Coll. Cardiol.,
November 15, 2005;
46(10):
1799 - 1802.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Jankowska, S. von Haehling, A. Czarny, E. Zaczynska, A. Kus, S. D. Anker, W. Banasiak, and P. Ponikowski
Activation of the NF-{kappa}B system in peripheral blood leukocytes from patients with chronic heart failure
Eur J Heart Fail,
October 1, 2005;
7(6):
984 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
